Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth
Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth
OBJECTIVES:

 I. Determine the efficacy of long term suppressive therapy with oral acyclovir in infants
 with herpes simplex virus infection limited to skin, eyes, and mouth.

 II. Determine the neurologic outcome in these patients when treated with this regimen.

 III. Evaluate the significance of a positive cerebrospinal fluid (CSF) polymerase chain
 reaction (PCR) result when all other CSF parameters remain normal in these patients.

 IV. Correlate the time to first positive CSF PCR result in the first 12 months of life with
 clinical neurological assessment in these patients when treated with this regimen.

 V. Determine whether the continuous administration of this drug suppresses recurrent skin
 lesions in these patients.

 VI. Determine the safety of this regimen in these patients.
PROTOCOL OUTLINE:

 This is a randomized, double blind, placebo controlled, multicenter study.

 All patients undergo a lumbar puncture and then receive acyclovir IV every 8 hours on Days
 1-14. On Day 12, patients may undergo a lumbar puncture (at discretion of investigator).
 Whole blood is obtained for herpes simplex virus PCR analysis. Upon completion of intravenous
 therapy, patients with a negative CSF PCR are randomized to one of two treatment arms.

 Arm I: Patients receive oral acyclovir three times daily for 6 months.

 Arm II: Patients receive placebo three times daily for 6 months.

 In case of cutaneous recurrence during the first 12 months of the study, patients receive
 open label oral acyclovir (if CSF PCR is negative) or acyclovir IV (if CSF PCR is positive)
 for 5 days. Patients may or may not continue on study drug following this treatment.

 Patients are followed at 6, 12, 24, 36, 48, and 60 months of age.
PROTOCOL ENTRY CRITERIA:

 --Disease Characteristics--

 Infants diagnosed with herpes simplex virus infection limited to skin, eyes, and mouth;
 HSV-1 or HSV-2 isolated from cutaneous lesions, conjunctivae, or oropharynx (presence of
 skin lesions not required); normal CSF indices: WBC less than 22/mm3 and protein less than
 115 mg/dL for term infants OR WBC less than 25/mm3 and protein less than 220 mg/dL for
 preterm infants; no evidence of CNS involvement by CT with contrast, MRI with gadolinium,
 or head ultrasound; no visceral dissemination (normal liver function tests, normal chest
 x-ray, etc.); negative CSF PCR result

 Birth weight at least 800 grams

 --Prior/Concurrent Therapy--

 No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or
 famciclovir for longer than 120 hours or 5 days; no prior prophylactic acyclovir for risk
 of herpes simplex virus infection

 --Patient Characteristics--

 Renal: Creatinine no greater than 1.5 mg/dL

 Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage

 Other: No infants known to be born to HIV-positive women